|
Cohort1: dose level 1
|
| Administration route |
intramuscular injection |
| Dosage |
5E10 vg/kg |
| Pts |
3 |
| Age |
Adult, Older_Adult |
| Adverse reactions |
2/3(Gastrointestinal disorders; Aspartate aminotransferase increased; Blood creatinine increased) |
| References |
PMID:
35411076
|
|
|
Cohort2: dose level 2
|
| Administration route |
intramuscular injection |
| Dosage |
5E11 vg/kg |
| Pts |
3 |
| Age |
Adult, Older_Adult |
| Adverse reactions |
2/3(Infections and infestations; Metabolism and nutrition disorders; Musculoskeletal and connective tissue disorders) |
| References |
PMID:
35411076
|
|
|
Cohort3: dose level 3
|
| Administration route |
intramuscular injection |
| Dosage |
2.5E12 vg/kg |
| Pts |
4 |
| Age |
Adult, Older_Adult |
| Adverse reactions |
4/4(General disorders; Blood creatinine increased; Musculoskeletal and connective tissue disorders; Nervous system disorders) |
| References |
PMID:
35411076
|
|